Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Study of Blinatumomab for Treatment of Adult Patients With Morphologic Relapsed/Refractory or Measurable Residual Disease (MRD) CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)

NCT04827745 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT04827745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04827745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Study of Blinatumomab for Treatment of Adult Patients With Morphologic Relapsed/Refractory or Measurable Residual Disease (MRD) CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Completed
Start date
June 11, 2021
Completion date
May 22, 2025
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

measurable residual disease (mrd), mixed phenotype acute leukemia (mpal)